Thyrocare Technologies share news, announcements and annual reports
NSE: THYROCAREBSE: 539871Healthcare ServicesSmall Cap
Thyrocare Technologies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2016 · Issue price ₹446
Last close ₹456.30down ₹59.20 (11.48%)BSE ₹457.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹515.50.
30 Oct: open ₹496.05, high ₹503.50, low ₹445.30
52-week range of traded prices to 30 Oct 2026
₹342.55Low, 23 Mar 2026₹662.00High, 12 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,263 Cr673rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 50.36
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹51 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 37.18
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.12
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 26.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹51 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 35.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 43.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,51,03840.9% delivered
Thyrocare Technologies disputes and clarifications
20 filed, newest first.
Nov 2025
13 Nov · Legal
The exchange asked on 13 Nov 2025
Jun 2025
Mar 2025
Feb 2025
19 Feb · Legal
Exchange has sought clarification from Thyrocare Technologies Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
Jun 2023
21 Jun · Legal
The exchange asked on 20 Jun 2023
Sep 2022
9 Sep · Legal
The exchange asked on 8 Sep 2022
Jun 2022
7 Jun · Legal
The exchange asked on 6 Jun 2022
May 2022
27 May · Legal
The exchange asked on 26 May 2022
Feb 2022
22 Feb · Legal
Jan 2022
28 Jan · Legal
The exchange asked on 27 Jan 2022
Oct 2021
8 Oct · Legal
Exchange has sought clarification from Thyrocare Technologies Limited with respect to announcement dated 07-Oct-2021, regarding appointment of Dr. Dhaval Rajesh Shah as an additional director of the company at its board meeting held on October 06, 2021. On basis of above the Company is required to clarify following: 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018.The response of the Company is awaited.
Sep 2021
9 Sep · Legal
Exchange has sought clarification from Thyrocare Technologies Limited with respect to announcement dated 02-Sep-2021, regarding outcome of Board meeting held on September 02, 2021. On basis of above the Company is required to provide confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018.The response of the Company is awaited.
Oct 2020
9 Oct · Legal
The exchange asked on 8 Oct 2020
Sep 2020
16 Sep · Legal
Exchange has sought clarification from Thyrocare Technologies Limited for the quarter ended 30-Jun-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Aug 2020
18 Aug · Legal
The exchange asked on 17 Aug 2020
Feb 2020
5 Feb · Legal
The exchange asked on 4 Feb 2020
Aug 2018
7 Aug · Legal
Exchange has sought clarification from Thyrocare Technologies Limited with respect to announcement dated 04-Aug-2018, regarding Board meeting held on August 04, 2018. On basis of above the Company is required to clarify following: 1. Pre & post shareholding pattern.The response of the Company is awaited.